Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma.
Journal
Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
27
07
2020
revised:
18
09
2020
accepted:
22
09
2020
pubmed:
4
12
2020
medline:
16
10
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
To investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy after autologous stem cell transplant (ASCT) in patients with plasma cell myeloma. Ten patients (median age, 59 years) received induction treatment followed by high-dose melphalan (200 mg/m NK cell numbers increased 56.0-fold (37.4- to 75.5-fold). Patients received a median of 3.8 × 10 This study demonstrates reliable manufacturing of high numbers of activated NK cells for multiple-dose infusions and safe administration of these cellular products. The trial was registered at ClinicalTrials.gov (identifier no. NCT01040026).
Sections du résumé
BACKGROUND AIMS
To investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy after autologous stem cell transplant (ASCT) in patients with plasma cell myeloma.
METHODS
Ten patients (median age, 59 years) received induction treatment followed by high-dose melphalan (200 mg/m
RESULTS
NK cell numbers increased 56.0-fold (37.4- to 75.5-fold). Patients received a median of 3.8 × 10
CONCLUSIONS
This study demonstrates reliable manufacturing of high numbers of activated NK cells for multiple-dose infusions and safe administration of these cellular products. The trial was registered at ClinicalTrials.gov (identifier no. NCT01040026).
Identifiants
pubmed: 33268029
pii: S1465-3249(20)30900-2
doi: 10.1016/j.jcyt.2020.09.009
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT01040026']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-338Informations de copyright
Copyright © 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.